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Abstract
Background A number of methods exist for the risk
assessment of hospital inpatients to determine the likeli-
hood of patients experiencing drug-related problems
(DRPs), including manual review of a patient’s medication
(medication reviews) and more complex electronic
assessment using decision support alerts in electronic pre-
scribing systems. A systematic review was conducted to
determine the evidence base for potential risks associated
with adult hospital inpatients that could not only lead to
medication-related issues but might also be directly asso-
ciated with pharmacist intervention.
Objectives The aims were to perform a systematic review
of the literature in order to (1) identify all measurable risk
factors associated with adult hospital inpatients that
potentially lead to a pharmaceutical intervention; (2) crit-
ically evaluate the quality of the identified research; and (3)
further subcategorise potential risk factors, so that phar-
maceutical services may be targeted to patients ‘‘at risk’’ by
identifying potential risk factors in a patient’s electronic
hospital record.
Methods A systematic review, conducted in June 2013,
searched ten medical literature databases for all papers
identifying risks leading to pharmacist interventions or
DRPs, adverse drug events (ADEs), adverse drug reactions,
drug errors (where not included in the definition of an
ADE), and medication-related problems. The search iden-
tified 7720 titles, from which 120 papers were sourced. A
hand search of a further 11 journals was also performed.
No date restrictions were imposed. All primary research
and literature reviews were included. Summary articles
were excluded with the exception of literature reviews. The
inclusion of search outputs was validated by a third party
pharmacy research graduate.
Results From the 7720 titles, 38 publications met the
inclusion criteria for the review. The ten most frequently
reported risk factors associated with medication-related
issues that may potentially lead to a hospital pharmaceu-
tical intervention are as follows (ranked in descending
order of frequency): prescription of certain drugs or classes
of drugs, polypharmacy, elderly patients (defined as over
65 years), female gender, poor renal function, the presence
of multiple comorbidities, length of patient stay, history of
drug allergy or sensitivity, patient compliance issues, and
poor liver function. The ten classes of drugs most fre-
quently reported to be associated with medication-related
issues leading to a hospital pharmaceutical intervention are
as follows (ranked in descending order of frequency):
intravenous antimicrobials, thrombolytics/anticoagulants,
cardiovascular agents, central nervous system agents, cor-
ticosteroids, diuretics, chemotherapy, insulin/hypogly-
caemics, opiates, and anti-epileptics.
Conclusion Review of the literature identified 38 papers,
from which the ten most frequently reported risk factors
linked with factors that are potentially associated with
hospital pharmaceutical interventions (all definitions
included) were identified. No papers were identified that
demonstrated a direct causal relationship between a
potential risk factor and hospital pharmaceutical interven-
tions. All of the potential risk factors associated with
& Emma Suggett
emma.suggett@uhb.nhs.uk
1 Pharmacy Department, University Hospitals Birmingham
NHS Foundation Trust, Queen Elizabeth Hospital
Birmingham, University of Birmingham, Mindelsohn Way,
Edgbaston, Birmingham B15 2WB, UK
2 School of Pharmacy, College of Medical and Dental
Sciences, University of Birmingham, Birmingham, UK
Drugs - Real World Outcomes
DOI 10.1007/s40801-016-0083-4
problems with the use of medicines can be identified from
patient records on admission to hospital. These risk factors
may be used to identify patients at risk, with a view to
targeting pharmaceutical intervention in order to minimise
risks of problems with medicines and improve efficiency of
clinical pharmacy services.
Key Points
A total of 38 papers identified the ten most
frequently reported measurable risk factors for
medication-related issues (all international
definitions included), all of which may be identified
from hospital inpatient records.
Twenty-eight of these papers identified the ten most
frequently reported drugs or classes of drug
associated with medication-related issues; further
work is required to quantify these risks.
No papers discussed the risk factors associated with
the requirement for pharmacist intervention. This
may be because of poor evidence for an association
of pharmacist interventions with a reduction in
medicines-related incidents.
1 Introduction
1.1 Background
In recent years, there has been an increasing drive to
improve the quality of care delivered by the United
Kingdom’s (UK’s) National Health Service (NHS), whilst
at the same time improving productivity and efficiency.
Quality, Innovation, Productivity and Prevention (QIPP) is
a national policy seeking to reduce costs in the NHS
through reduction in readmission to hospital. Several
studies have aimed to determine the risk factors leading to
hospital admission, and these studies are valuable in
meeting the QIPP agenda [1].
It has been shown that more than 6 % of all hospital
admissions are due to issues related to medication [2] prior to
admission, with the result that there have been an increasing
number of community-based methodologies trialled inter-
nationally to identify and target patients with risk factors for
intervention [3–8]. Most of these studies have used incident
report review, prescription chart review, direct observation
or trigger tools to identify at-risk patients. The trigger tool
method, in which patients are screened for perceived risk
factors for medication problems, has been shown to be the
most effective and labour-efficient method for identifying
vulnerable patients [9]. In some cases, the use of electronic
prescribing systems (EPs) and clinical decision support
(CDS) has resulted in the development of a number of
‘‘trigger tools’’ driven by rule-based alerts programmed into
a CDS system [10–12].
The purpose of this review was to determine the evi-
dence base for problems associated with medicines after
admission to hospital and to identify factors directly
determining the most vulnerable patients requiring targeted
intervention by a pharmacist. The intention would be to
determine if these risk factors could be identified from the
patient’s medical notes (potentially electronic medical
notes where an EP or CDS system is in place) to assist in
targeting pharmacist intervention in order to improve the
quality and efficiency of clinical pharmacy services.
Pharmacists will generally intervene in the case of
medication problems inclusive of all definitions. As such,
the review included and sought to make comparison
between studies using all terminologies and definitions of
issues related to drug treatment [such as adverse drug
events (ADEs), adverse drug reactions (ADRs), drug
errors, drug-related problems (DRPs), and medication-re-
lated problems (MRPs)]. However, in addition to targeting
problems associated with specific drugs or regimens,
pharmacists may intervene for reasons generally associated
with non-clinical patient characteristics such as commu-
nication difficulties, confusion, or their refusal to comply
with recommended treatment. Just as the risks associated
with drug errors may differ slightly from those associated
with ADRs, we should not assume that the risks associated
with pharmacist intervention are identical to those leading
to medicines-related issues. Any reviews identifying risks
directly associated with the requirement for clinical phar-
macist intervention were also included.
A number of corporate approaches to assess the risks
associated with drug usage in the hospital setting already
exist. Retrospective assessment of incident reports in the
UK is widespread, with the majority of hospitals identify-
ing local trends in drug-related incidents. Reporting ADRs
to the Medicines and Healthcare Regulatory Agency
(MHRA) and drug-related incidents to the National Patient
Safety Agency (NPSA) [now replaced by NHS England
(NHSE)] has been routine practice for many years, with the
result that there is an increased awareness of high-risk
prescribing amongst pharmacists and prescribers. The
NPSA and now NHSE have issued alerts [13] pertaining to
high-risk drugs, drug omissions, patients who are nil by
mouth, and the administration of medicines using syringe
drivers. Similarly, the Institute for Safe Medicines Prac-
tices (ISMP) in the USA [14] and the Australian Com-
mission on Safety and Quality in Health Care (ACSQHC)
[15] have used a similar system of alerts, raising awareness
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of the risk associated with medicines in organisations
internationally.
This increasing awareness of risk in hospitals has led
researchers in the UK to pilot a national trigger tool, the
Medication Safety Thermometer [16]. The tool aims to
direct pharmacists by identifying patients at risk of harm
following the omission of high-risk drugs. These high-risk
drugs were defined using data pooled from reports to the
NPSA. This may prove to be a valuable tool in reducing
patient harm, but does not address all of the risks that a
pharmacist should target. Certain forms of risk reduction
with direct clinical interventions to patients deemed to be
‘‘at risk’’ have developed as roles of the UK hospital
pharmacist have evolved. Patients with polypharmacy,
those with impaired renal or liver function, and those
taking anti-epileptics or medication for Parkinson’s disease
may already be in receipt of increased pharmacist moni-
toring albeit on a qualitative ad hoc basis. Assessment of
the impact of pharmaceutical intervention is also difficult
since intervention is usually a preventative action, which
influences the measurement of patient outcomes. The result
is that the value of clinical pharmacy services is not well
documented, communicated, or perceived by hospital
managers in the UK.
Inpatients are unlikely to be rationally documented as
‘‘high risk’’ or in need of targeted intervention by a phar-
macist with the possible exception of cases where a phar-
maceutical care plan has been employed. However,
producing a pharmaceutical care plan is extremely labour
intensive and is therefore often only completed for com-
plex cases in most hospitals in the UK. National initiatives
such as the reduction of dosage omissions and targeting
high-risk drugs and supporting patient adherence are
increasingly taking up the time of clinical pharmacists. In a
risk driven, resource-limited environment, targeting clini-
cal pharmacy services to ensure safe, timely, high-quality
services centred on patient safety should be paramount. To
identify all patients who require clinical pharmacist inter-
vention and therefore target valuable pharmacy resources,
we must identify all of the drug-related risks associated
with the patient and their treatment.
1.2 Aims
The purpose of this systematic review was to determine the
evidence base for measurable risk factors that pre-dispose
patients to the requirement for a clinical pharmacist inter-
vention in their treatment.
The intention is to use these outcomes in further
research to build an evidence-based trigger tool, targeting
individuals at risk of experiencing a problem with their
medicines while in hospital. Risk scores are being
increasingly researched with a view to targeting high-risk
patients [17, 18]; however, the intention for future research
is to develop a score that encompasses all definitions of
drug-related issues to direct pharmacy services.
The key aims were to search the international literature
to:
1. Identify measurable risk factors for medicines-related
issues that may signal the necessity for a pharmacist
intervention.
2. Document the frequency of such risk factors.
3. Identify those risk factors that could be accessed from
a patient’s medical notes.
1.3 Objectives
The objectives are to:
1. Search for and document all primary research or
literature reviews identifying measurable risk factors
that can be associated with problems associated with
medicines or the requirement for a clinical pharmacist
intervention.
2. Critically evaluate the quality of the identified research
through intensive reading.
3. Further subcategorise the identified risk factors to
enable their identification or measurement in a
patient’s electronic hospital record.
2 Methods
The systematic review was carried out using the principles
and checklist set out in the PRISMA statement [19].
Figure 1 outlines the methodology and summarises results
at each stage of the review.
2.1 Eligibility Criteria
The PICOS method [20] was used to formulate the review
question and identify free-text search terms through a
combination of mind-mapping by E.S. and information
from a focus group consisting of ten members of the UK
West Midlands Clinical Pharmacy Group.
2.1.1 Paper Inclusion Criteria
Inclusion criteria included quantifiable risk factors, patients
over 16 years, inpatients in secondary or tertiary care
centres, inpatients in medical and surgical wards, all defi-
nitions of DRPs, ADEs, ADRs, MRPs, and clinical phar-
macy interventions (defined as ‘‘The process of a
pharmacist identifying, and making a recommendation in
an attempt to prevent or resolve, a drug-related issue’’; the
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definition of an intervention does not include a routine,
pharmacist review of medication without recommendation
for a change in the patient’s treatment), all primary
research, and systematic reviews.
2.1.2 Paper Exclusion Criteria
Exclusion criteria included qualitative risk factors (e.g.
patient’s previous knowledge of medicines), studies
reporting outcomes indirectly associated with pharmacist
interventions or adverse events associated with medicines,
e.g. medicines adherence, studies of patients 16 years or
younger, outpatients, ambulatory care and community-
based studies, studies solely in patients in specialist care
settings, e.g. intensive care, summary articles (with the
exception of systematic reviews), and discussion articles.
2.1.3 Search Terms
Free-text search terms comprised the following: risk, risk
assessment, clinical risk, susceptibility, drug, medicine,
medicines reconciliation, drug history, clinical check, age,
elderly, adult, compliance aids, medicines adherence,
comorbidity/ies, long term conditions, therapeutic drug
monitoring (TDM), renal function, liver function, pre-
scription, early warning score, dose/dosage, pharmacy
review, biochemistry, urea and electrolytes, tests, micro-
biology, intervention, adverse drug event, adverse drug
reaction, drug error, medication error, and pharmacy
service.
MeSH descriptors were identified from free-text terms
inputted into the databases listed below and comprised the
following: risk, risk factor, hospital risk, risk assessment,
lifestyle risk reduction, risk reduction, clinical prediction
rule, clinical prediction, health risk, health risk appraisal,
pharmaceutical preparations, medicine, drug administra-
tion schedule, drug administration routes, drug combina-
tions, drug hypersensitivity, drug interactions, drug
synergism, drug therapy drug toxicity, medical history
taking, drug prescriptions, decision support techniques,
clinical pharmacy, medical informatics, pharmacists,
pharmacy service hospital, pharmacy service, hospital,
clinical pharmacy information systems, drug utilization
review, pharmaceutical services, intervention studies,
pharmacy service, hospital and medication errors.
2.2 Information Sources
Initially online searches were conducted in databases 1–10
included in the list below.
Following the database search, a manual search was
conducted of journals 11–21, using online access.
Databases searched:
1. MEDLINE—http://www.ncbi.nlm.nih.gov/PubMed
2. EMBASE—http://www.embase.com
3. Cochrane Data Base of Systematic Reviews—http://
www.cochrane.co.uk/en/index.html
4. CINAHL—http://www.cinahl.com
5. Dissertation Abstracts—http://www.umi.com/en-US/
catalogs/databases/detail/pqdt.shtml
6. Science Citation Index—http://thomsonreuters.com/
en/products-services/scholarly-scientific-research/
scholarly-search-and-discovery/web-of-science-core-
collection.html
7. Conference Papers Index—http://ca2.csa.com/
factsheets/cpi-set-c.php
8. UK Clinical Research Network: Portfolio Database—
http://public.ukcrn.org.uk
9. National Research Register Archive—http://www.
nihr.ac.uk/Pages/NRRArchive.aspx
10. SIGLE (System for Information on Grey Litera-
ture)—http://www.opengrey.eu.
Journals manually searched:
11. Clinical Pharmacist—http://www.pharmpress.com/
product/13527967/clinical-pharmacist
12. Hospital Pharmacist—http://www.pharmj.com/
backissues/hp.html
13. British Journal of Clinical Pharmacy—http://www.
clinicalpharmacy.org.uk/home
14. British Journal of Clinical Pharmacology—http://
onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-
2125
15. European Journal of Hospital Pharmacy—http://
ejhp.bmj.com/
16. American Journal of Hospital Pharmacy—currently
without website accessed at: https://www.
researchgate.net
17. American Journal of Health-System Pharmacy—
http://www.ajhp.org/content/by/year
18. Australian Journal of Hospital Pharmacy—cur-
rently without website accessed at: http://search.
informit.com.au/browseJournalTitle;res=IELHEA;
issn=0310-6810
19. Journal of Pharmacy Practice and Research—
http://search.informit.com.au/browseJournalTitle;
res=IELHEA;issn=1445-937X
20. International Journal of Clinical Pharmacy (known
as Pharmacy World and Science Prior to 2011)—
http://www.springer.com/medicine/internal/journal/
11096
21. International Journal of Pharmacy Practice—http://
onlinelibrary.wiley.com/journal/10.1111/(ISSN)2042-
7174.
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2.3 Study Selection
Between April and June 2013, searches were undertaken in
chronological order using the same search terms listed
above for all databases.
No date or language restrictions were applied during the
review. However, the search was closed in July 2013 and
identified no papers prior to 1966. Further online searching for
additional papers not already identified was conducted for grey
literature using the free-text search terms listed above and, in
particular, for internet publications linked to pharmaceutical
interventions, using Google and Firefox as search engines.
After screening the abstracts, all potentially relevant
full-text publications were evaluated through intensive
reading by E.S. Citations included in the retrieved articles
were reviewed and, if relevant, were sourced, evaluated,
and the citations checked.
All sourced articles were tabulated to allow validation of
a final list of citations and for a final list of included papers
to be drawn up. The validation of this final list was carried
out by an independent pharmacy research graduate who,
using the agreed inclusion/exclusion criteria, evaluated the
articles against their respective abstracts. Where the
abstract did not provide sufficient information for the
article to be evaluated against the inclusion/exclusion cri-
teria, the full text was provided to the research graduate.
Finally, the research graduate and E.S. met to discuss
any remaining articles to resolve disagreements; it was not
necessary to resort to a third party reviewer as disagree-
ments were resolved.
In order to quantify the results of the review, thematic
analysis was undertaken. Through intensive reading, risks
were identified as such as those listed as independent risk
factors in the research conclusions and subsequently tab-
ulated to allow for common themes (risks) to be identified.
2.4 Data Collection Process
Included risk factors were not required to have been shown
to be a statistically significant independent risk factor,
although where reported statistical methods excluded or
included a risk factor as an independent risk factor, this
was noted in the conclusions.
2.5 Synthesis of Results
The association of risk factors was noted in the results
table. A ‘‘negative’’ association was noted where the
research had shown:
1. No association between the potential risk factor and
issues related to the use of medicines or the require-
ment for a pharmacist intervention;
2. The potential risk factor was not an independent risk
factor for issues related to the use of medicines or the
requirement for a pharmacist intervention; or
3. The potential risk factor was a protective factor for
problems associated with the use of medicines or the
requirement for a pharmacist intervention.
The frequencies of positive and negative associations
with risk factors were documented in Table 1 in order to
identify the most frequently reported risk factors.
All risk factors identified in the literature by more than
one primary research paper were listed under their
respective description and all others noted as ‘‘other’’.
Those studies that demonstrated an association between
certain drugs or drug classes and problems with their use
were further tabulated (Table 2) to identify these ‘‘high-
risk’’ drugs.
3 Results
Figure 1 summarises the publication outputs at each stage
of the review process.
Using search terms ‘‘risk’’ and ‘‘adverse drug events’’,
44,731 articles were identified initially from online sear-
ches. This was reduced to 7720 through the use of ‘‘AND’’
as the Boolean operator to link to a third relevant search
term.
All resulting titles were viewed and 120 abstracts
identified for possible inclusion in the review from
searching online search engines.
A further 29 full-text papers were identified from man-
ual searching of journals 11–21.
The search of Google and Firefox provided no addi-
tional references. In total 149 full texts were sourced.
Preliminary screening of the paper abstracts and cross-
referencing of the citation by E.S. identified a resulting 82
papers, which were tabulated and independently evaluated.
Intensive reading of the resultant 82 papers eliminated a
further 46 in accordance with the study inclusion/exclusion
criteria.
The same 46 publications were independently elimi-
nated by the research graduate, while two papers of the 82
were included back into the final results after discussion
and agreement with the primary author.
The resulting 38 papers (including four literature
reviews) were tabulated in Table 1 and intensive reading
identified any potential risk factors.
Ten risk factors were identified in more than one
research paper (in descending order of prevalence): pre-
scription of certain drugs or classes of drugs, polyphar-
macy, elderly patients (defined as over 60–75 years or
older), female gender, poor renal function, the presence of
E. Suggett, J. Marriott
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multiple comorbidities, length of patient stay, history of
drug allergy or sensitivity, patient compliance issues, and
poor liver function.
Table 2 lists the 28 studies that reported that the pre-
scription of certain drugs or classes of drugs were a risk
factor in developing a problem with a medicine that may
require pharmaceutical intervention. The ten most common
classes of drugs reported to be associated with problems in
the hospital setting are as follows (in descending order of
frequency): intravenous antimicrobials, thrombolytics/an-
ticoagulants, cardiovascular agents, central nervous system
(CNS) agents, corticosteroids, diuretics, chemotherapy,
insulin/hypoglycaemics, opiates, and anti-epileptics.
4 Discussion
A clinical intervention is the process of a pharmacist
identifying, and making a recommendation in an attempt to
prevent or resolve, a drug-related issue. The definition of
an intervention does not include a routine pharmacist
review of medication without recommendation for a
change in the patient’s treatment. Clinical pharmacist
interventions are therefore more time consuming and costly
to perform than routine pharmacist reviews of a drug chart.
Although there are many research papers that detail the
risks associated with DRPs, ADEs, ADRs, drug errors, and
MRPs, there is little work exploring the requirement for a
pharmacist intervention in these contexts. Pharmacist
intervention is appropriate should any of these medication-
related issues occur and perhaps for others we have yet to
identify. This search aimed to identify these risks with a
view to future targeting of patients most in need of inter-
vention, thus maximising limited resources.
4.1 High-Risk Drugs
The ten risk factors most frequently associated with DRPs,
ADEs, ADRs, drug errors, and MRPs are not surprising and
yet are poorly documented as such in the literature. The
identity of the drugs themselves and the associated class
effects are the single largest risk factor and yet it is not
possible from the literature to quantify the risk associated
with the use of an individual drug or drug class. For
example, intravenous antibiotics are the most frequently
reported drug class linked with medicines-related prob-
lems, while thrombolytics and anticoagulants constitute the
second most prevalent group. However, none of the review
papers quantify those risks. Further research would be
beneficial to identify a risk score for each drug class to
facilitate comparisons and measures for prevention. Simi-
larly, there is no information comparing the risks associ-
ated with drugs within each class.
The four most commonly named drug groups associated
with issues were antimicrobials (mainly intravenous
antibiotics), anticoagulants and thrombolytics, cardiovas-
cular drugs, and drugs acting on the CNS. Definitions of
these classes of drugs are unclear in almost all of the papers
reviewed, making interpretation of the findings and further
research problematic. In most papers, the researchers did
not consider whether the drug was an independent risk
factor. For example, in the case of antimicrobials, none of
the researchers considered the possibility that the presence
of infection may have been the causative factor leading to
an adverse event.
It is important that any conclusions made from this
review are interpreted in general medical and surgical
settings only. In order to obtain meaningful data,
researchers have examined groups of patients taking
widely available and frequently prescribed medicines in
hospital. None of the review papers reported the frequency
of prescribing for a particular drug class, i.e. there was no
reported denominator. It is possible that the large number
of issues associated with diuretics, for example, is associ-
ated with their widespread use. Some newer drugs to the
market such as monoclonal antibodies, anti-retrovirals and
anti-rejection drugs, which might be expected to be asso-
ciated with a large number of problems associated with the
use of medicines compared with the number of prescrip-
tions, are not included in any of the review papers, and
therefore the results do not necessarily mirror alerts for
high-risk drugs issued nationally and internationally
[13–15].
The present review identified papers within the limita-
tion of date restrictions of the databases searched, which
included papers from 1966 to the close of search (July
2013). Despite concerns that this might have a direct
impact on the range of drugs identified as high risk, only
the inclusion of diuretics as a high-risk category was
unexpected. On review of the date of the articles citing
diuretics as a high-risk drug category, four of the eight
publications were published post 2005; should all papers
prior to 2005 in the review be excluded, diuretics would
remain as a top 10 high-risk drug.
Since undertaking the present review, another system-
atic review of high-risk drugs associated with medication
errors has been published [17]. The drugs highlighted as
high risk in the review are different to those identified in
the present review. The review [56] only searched for risks
associated with preventable problems, with the assumption
that intervention prior to a non-preventable problem would
be futile. The present review examines risks associated
with both preventable and non-preventable issues with
medicines since in cases where problems may not be pre-
ventable, prompt recognition and possible removal of the
causative agent seems sensible.
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One approach to increasing awareness of the risks
associated with individual medicines could be that in the
future, all drugs are risk assessed before reaching the
market as part of the clinical trial process. Products could
be assigned a risk score prior to the issue of market
authorisation, using a process similar to that undertaken for
intravenous medication under UK NPSA Alert 20 [13]. In
light of post-marketing studies and national incident
reporting systems, modifications of risk scores could
accompany national patient safety alerts.
4.2 Polypharmacy
It is widely accepted that polypharmacy has a direct effect
on the number of DRPs, ADEs, ADRs, drug errors, and
MRPs. This not only seems a logical assumption, but it is
also undisputed in the literature where polypharmacy has
been shown to be an independent risk factor for the
development of problems related to medicines
[18, 24, 25, 28, 29, 32–34, 46, 54, 56]. Various definitions
of polypharmacy exist, ranging from prescription of three
to six or more medicines. However, it is more likely that
there is a continuous relationship [56], possibly exponential
[57], between the number of drugs taken and the risk of a
problem developing.
4.3 Age
Older age (definitions vary from 60 years to over 75 years)
was reported as a risk factor in 14 studies; however, a
further six studies [24, 25, 28, 29, 34, 55] reported that age
is not an independent risk factor for medicines-related
issues. The six studies that demonstrated that age is unli-
kely to be an independent risk factor used multi-variant
analysis and logistic regression to show that the association
of older age with medication problems is more likely to be
associated with the increased incidence of multiple
comorbidities, multiple medications, poor renal function,
and compliance issues in elderly persons rather than a
direct association with their age per se. This was supported
by a literature review [36] over 20 years ago, which
recognised that most studies examining age and ADRs
(including all definitions) failed to control for multiple
drugs and multiple comorbidities. As the elderly population
increases and research in this area continues, it is likely that
the risks associated with the use of drugs in old age will
become clearer. However, it seems logical that as life
expectancy increases, exceeding age 65 years is unlikely to
influence the likelihood of suffering an ADR, whereas, the
prevailing general state of health will.
One study [31] reported that the age group 18–50 years
was a risk factor for ADEs, but it is likely that this was due to
the fact that the study group comprised only diabetic patients.
4.4 Renal Function
Poor renal function was the fourth most frequently reported
risk factor, listed in nine papers [18, 23–25, 35, 44, 46, 47, 51].
However, as long ago as 1966, Smith et al. [51] recognised that
this risk factor is only likely to increase the rate of ADRs when
using certain groups of drugs that are eliminated renally.
However, any patient with poor renal function may potentially
be prescribed one of these drugs and, as such, may already be
deemed at risk of a problem related to drugs prior to pre-
scription. The recommended dosage or frequency adjustments
in renal failure are well documented for affected agents so that
this risk may be minimised if appropriately identified. This
was supported by Fields et al. [35], who recognised the
importance of early estimation of creatinine clearance (CrCl)
through computerised order entry to identify renal function as
a risk factor for preventable ADEs.
4.5 Gender
Female gender is the fifth most frequently reported risk
factor for DRPs, ADEs, ADRs, drug errors, and MRPs,
with nine papers reporting an association [25, 26,
31–34, 38, 44, 57]. However, it is possible that the link
with female gender may be weak since one paper demon-
strated that gender was not an independent risk factor for
ADRs [28], while another reported that ADEs occurred
more often in men than in women [40]. However, numbers
in the later study [40] were small and most adverse events
were due to drug errors, which are unlikely to be affected
by the gender of the patient. Further detailed research is
required to define the precise relationship.
4.6 Comorbidities
Seven papers included multiple comorbidities as a risk
factor for problems associated with the use of medicines
[21, 24, 26, 28, 30, 44, 55]. However, Camargo et al. [28]
used multivariate logistic regression and identified that
multiple diagnoses were unlikely to be an independent risk
factor for ADRs. It is possible that the increased number of
medicines taken by patients with multiple comorbidities
could have a bearing on the number of problems experi-
enced by patients. Conversely, it is also possible that a
patient’s susceptibility to ADRs is increased by their poor
overall health and that drug metabolism may be affected by
their condition or additional unknown factors. It would be
advisable for more research to be carried out in this area.
4.7 Length of Stay
Length of hospital stay was also reported as a risk factor
[26, 28–30, 33]. This seems a logical connection in that any
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adverse event (drug related or otherwise) is more likely to
occur the longer the patient is observed, which in the case
of hospital inpatients, would be dependent on their length
of stay. However, one paper [28] reported that there is an
association with follow-up period (period of time as an
inpatient after an ADR). In this case, it is possible that the
occurrence of an ADR caused the increase in length of stay
through treatment failure, drug toxicity, or other factors.
None of the review papers reported that patients were more
likely statistically to experience a problem the longer the
patient stayed in hospital, i.e. the intra-patient risk at any
point in time does not increase with the length of inpatient
stay. However, it is also likely that patients who have
longer hospital stays suffer from complex conditions or are
more unwell, making them more susceptible to DRPs
throughout their stay; under such circumstances, length of
stay is not an independent risk factor.
4.8 History of Allergy and Compliance Issues
Other risk factors for DRPs, ADEs, ADRs, drug errors, and
MRPs included in the literature were a previous history of
allergy or ADR and compliance issues, which were listed
as risk factors in four [18, 24, 38, 47] and three [24, 29, 57]
papers, respectively. Patients who may have a genetic
predisposition to ADRs or who display atopic character-
istics may be more likely to experience ADRs. One paper
[51] noted that although there was not an overall increase
of ADRs in this group, there was an increase in allergic
reactions.
Compliance issues included assumed non-compliance,
low cognition, and other factors affecting patients taking
their medicines such as alcohol abuse and swallowing
difficulties. Such barriers to compliance intuitively would
predispose patients to problems with medication regimens.
4.9 Liver Function
The association of deteriorating liver function with DRPs,
ADEs, ADRs, drug errors, and MRPs is less well docu-
mented. Only three papers [18, 24, 51] list deteriorating
liver function as a risk factor. In an analogous situation to
renal impairment, poor liver function is likely to only be
associated with an increased risk when certain drugs are
used, i.e. those whose elimination or distribution is hepatic
or affected by the reduction in protein metabolism, which
accompanies deterioration of liver function. Again this
relationship was recognised by Smith et al. [51], who noted
in his study that although the overall rate of ADRs was not
increased by decreasing liver function, the rate for certain
groups of drugs was increased slightly.
Drug management in hepatic failure generally differs to
therapy in renal failure. Often the risks of hepatotoxicity
drive the decision to treat with a drug or not, in contrast to
dosage or frequency adjustments required to avoid imme-
diate toxicity or treatment failure encountered in renal
failure. Prescribers often only have one of two options
when considering a drug for use in liver failure—‘‘To use
or not to use?’’—essentially a 50 % chance of making the
correct decision and avoiding toxicity that may (or may
not) result in an adverse event related to the use of medi-
cines. The likelihood of ADEs in patients with renal failure
as opposed to liver failure seems much greater owing to
errors in prescribing. These issues are compounded in renal
failure owing to drug accumulation or treatment failure as
CrCl reduces.
4.10 Other Risk Factors
Other risk factors that were uniquely identified (and were
therefore not tabulated as top 10 risk factors in this review)
included admission to a medical ward [32], geriatric ward,
rheumatology ward or gastroenterology ward [33], source
of admission (e.g. from home, general practitioner, clinic,
etc.) [40], insurance class (US) [40], infection [51], chan-
ges in patient’s biochemical/haematological parameters
[53], new drug initiation in hospital [54], single marital
status [31], use of drugs with a narrow therapeutic index
[44], and TDM requirement in the absence of a pharma-
cokinetics service [47]. Since these associations were only
reported in single studies, there may have been explana-
tions for the reported risk factors. It seems likely that drugs
with a narrow therapeutic index or requiring TDM are
indeed generic risk factors in all specialities and that
starting a new drug in any setting poses a risk owing to
drug error or poor compliance. However, it is less obvious
that factors such as single marital status are independent
risk factors for DRPs. Perhaps married patients may be
older and their lifestyle more predictable, providing a
supportive environment for improved compliance.
4.11 Limitations to the Review
The present review methods relied on the use of a number
of electronic databases, all of which used English as the
primary language, and all of the journals searched were
publications in the English language. As a consequence,
although the databases included citations from interna-
tional journals, it is likely that there is a bias towards
publications in English and that other work, in particular
from the Far East, may have been overlooked. However,
the review did not exclude publications from non-English
outputs. When the full texts were received, 44 citations
were identified from cross-referencing. It was found that 30
of these papers were available through databases listed in
the review, indicating that the online database search had
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not captured all relevant papers. However, these databases
have been rechecked using various other combinations of
the search terms listed in an attempt to confirm that no
other papers remain. In particular, cross-referencing iden-
tified a number of older articles that have been included in
this review but whose significance may be debatable owing
to differences in drug treatments available historically.
No outputs listing risk factors requiring intervention by
a pharmacist were detected using these methods. It is
possible that research into pharmacist interventions would
assume a direct correlation between pharmacist interven-
tion and an ADE. Researchers may deem it more appro-
priate to assess risk factors leading to the latter since the
presence of an adverse event indicates that either there has
been no preventative intervention or an intervention has
been unsuccessful in prevention of the adverse event.
Whichever is the case, without a proven correlation
between pharmaceutical intervention and the outcome of
an adverse event, research methodology may be better
directed at risk factors leading to adverse events caused by
medicines use.
Similarly, as research into pharmacist interventions is
more likely to be carried out by pharmacists themselves
who already target patients perceived to be at risk, this may
result in bias. Intervention research is more likely to be
targeted at those areas pharmacists may be missing, i.e.
actual reported problems associated with medicines rather
than pharmacist interventions, i.e. the near miss. Pharma-
cists may wish to determine whether problems are pre-
ventable, non-preventable, or partially preventable through
pharmaceutical intervention before targeting clinical
pharmacy services to patients with risk factors for
medicines-related issues. Certainly, research in this area is
lacking and has resulted in difficulties in quantifying the
worth of clinical pharmacy services.
5 Conclusions
Review of the literature found 38 papers that detailed ten
measurable risk factors linked with DRPs in hospital
inpatients that were identified in the literature by more
than one primary research article. DRPs included all
international definitions of ADEs, ADRs, DRPs, and
MRPs. No papers were detected that identified risk factors
for pharmacist interventions. There is a need for studies to
be carried out in this area in order that clinical pharmacy
services may be directed appropriately. Although risks
associated with incidents and issues that arise from
treatment with medication may be similar, it is likely that
there are additional risk factors that cause pharmacists to
intervene that are not associated with the drug treatment
in use. For example, a patient may not be taking any
medication at all and raise a question regarding lifestyle
choice or dietary advice. This review showed that
research into activity carried out by clinical pharmacists
in hospital is lacking.
However, all of the potential risk factors identified from
this review may be identified from most patients’ records
on admission to hospital. It is hoped that these risk factors
may be used to indicate patients most at risk, with a view to
targeting pharmaceutical input in order to minimise
medicines-related problems. With the advent of CDS sys-
tems, quantifying such risk factors could enable the
restructure of clinical pharmacy services into a model
targeting patients most at risk in real time rather than the
ward/unit in which they are located, which is most often
the case in the UK.
Potential risk factors include prescription of certain
drugs or classes of drugs, polypharmacy, elderly patients
(defined as over 60–75 years or older), female gender, poor
renal function, the presence of multiple comorbidities,
length of patient stay, history of drug allergy or sensitivity,
patient compliance issues, and poor liver function.
Hospital use of medications that are associated with a
high risk include antimicrobials (intravenous antibiotics),
anticoagulants and thrombolytics, cardiovascular drugs,
and drugs acting on the CNS. More research is required to
ensure that newer drug classes are included in research into
risks associated with the use of medicines and whether the
risks associated with the use of high-risk drugs are
preventable.
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